key: cord-0963785-crptyvck
authors: Beyls, Christophe; Huette, Pierre; Arab, Osama Abou; Berna, Pascal; Mahjoub, Yazine
title: ECMO for COVID-19 associated severe ARDS and risk of thrombosis
date: 2020-05-04
journal: Br J Anaesth
DOI: 10.1016/j.bja.2020.04.079
sha: ae305d8f3d69ff4a13585a222f62c36407e55805
doc_id: 963785
cord_uid: crptyvck

nan

appeared in Wuhan in China. 1, 2 Most COVID-19 patients present with mild or moderate symptoms, but the number of severe cases with acute respiratory distress syndrome (ARDS) requiring ventilation support rapidly increased during the last few weeks. 3 Veno-venous extracorporeal membrane oxygenation (ECMOvv) has been successfully used in ARDS during the flu swine epidemic of 2009, 4 however, there is very little reported experience regarding the use of ECMO for COVID-19 related ARDS. Thrombosis is a major concern for ECMO management. In the EOLIA trial (ECMO to rescue lung injury in severe ARDS), an international randomised clinical trial evaluating the effect of early initiation of ECMOvv in patients with severe ARDS, 14% of patients experienced cannula thrombosis. 5 Severe COVID-19 infection appears to be associated with hypercoagulation and an increased risk of thromboembolism. 6 This hypercoagulable state may be enhanced by inflammation and platelet aggregation related to the circuit during ECMO therapy. To date, there are no data regarding an increased risk of thrombosis in patients treated with ECMO for refractory ARDS due to COVID-19 infection.

In this preliminary report, we summarize our early experience regarding thrombotic complications during ECMOvv treatment of patients with COVID-19. We intend to alert frontline ECMO teams about a probable increased thrombotic risk related to COVID-19 infection in severe ARDS. Written informed consent was waved by the Amiens University Hospital IRB (Comite de Protection des Personnes Nord-Ouest II CHU-Place V. Pauchet, 80054 AMIENS Cedex 1) in accordance with French law on clinical research for noninterventional studies. 7 We present preliminary data (Table 1) ECMOvv treatment. Among these, 2 (17%) led to death, one due to massive pulmonary embolism during insertion of femoral cannula, and one due to major oxygenator thrombosis several minutes after starting the ECMOvv therapy. We also had two cases of cannula thrombosis (17%): one (8%) required urgent cannula change. Five (42%) patients had documented deep venous thrombosis at cannula sites despite heparin treatment. We observed an inflammatory and hypercoagulable state for all patients with high levels of C-reactive protein 280 mg l -1 [214-345], fibrinogen 7 g l -1 [6-9] D-dimer 8.3 µg l -1 [4.7-24] and fibrinogen degradation product (51µg ml -1 ). Due to the limited sample size, we were not able to identify any specific risk factor of thrombosis.

A hypercoagulable state in COVID-19 infected patients with the presence of deep venous thrombosis at cannulation sites appears to be associated with an increased risk of major thrombotic events. Studies have assessed long-term thrombotic complications during EMCO therapy but data on the incidence of thrombotic complications during cannula insertion are scarce. 8 Based on our experience, we suggest that venous Doppler ultrasonography of jugular and femoral veins should be performed routinely for refractory COVID-19 related ARDS in order to prevent issues in case ECMO therapy is needed. Venous ultrasound may help when starting and adapting anticoagulation therapy and provide insight for cannula insertion. In their interim COVID-19 guidelines, the extracorporeal life support organisation (ELSO) recommended following existing anticoagulation guidelines, with consideration given to targeting anticoagulation to the higher end of normal ECMOvv parameters given the hypercoagulable status of COVID-19 patients. 9 Moreover, in our centre we decided to rinse cannulae with heparin before starting ECMOvv. We also suggest repeated UFH dosing before cannula insertion. The ECMO team should be aware of this thrombosis risk, and further studies investigating the thrombotic risk in this setting are mandatory.

The authors declare that they have no conflicts of interest. 

In ECMO center (n; %)

Out-of-ECMO center (n; %) 

A Novel Coronavirus from Patients with Pneumonia in China

Outbreak of a new coronavirus: what anaesthetists should know

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Improved survival rates in patients with H1N1 acute respiratory failure in Korea between

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

French legal approach to clinical research

Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis

ELSO COVID-19 Interim Guidelines